Can you provide the last earnings date for MEDICENNA THERAPEUTICS CORP?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) last reported earnings on 2/12/2026.
MEDICENNA THERAPEUTICS CORP (MDNA.CA) Earnings History & Surprises
TSX:MDNA • CA58490H1073
Current stock price
0.77 CAD
-0.03 (-3.75%)
Last:
MDNA.CA Earnings overview
Past quarterly earnings results for MEDICENNA THERAPEUTICS CORP (MDNA.CA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Jun 23, 2026
- Period
- Q4 / 2026
- EPS Estimate
- -CA$0.05
- Revenue Estimate
Last Reported
Most Recent- Release Date
- Feb 12, 2026
- Period
- Q3 / 2026
- EPS Reported
- -CA$0.05
- EPS Surprise
- 18.30%
- Revenue Surprise
- %
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in CAD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | -0.05 | -0.06 | 18.30% | 28.57% | - | - | ||
| Q2 2026 | -0.06 | -0.06 | 7.12% | -20.00% | - | - | ||
| Q1 2026 | -0.06 | -0.05 | -17.65% | -20.00% | - | - | ||
| Q4 2025 | 0.02 | -0.06 | 132.68% | 110.00% | - | - | ||
| Q3 2025 | -0.07 | -0.07 | -2.94% | - | - | - | ||
| Q2 2025 | -0.05 | -0.06 | 18.30% | - | - | - | ||
| Q1 2025 | -0.05 | -0.06 | 18.30% | -25.00% | - | - | ||
| Q4 2024 | -0.20 | -0.06 | -256.51% | -233.33% | - | - | ||
| Q3 2024 | -0.07 | -0.07 | 5.34% | -250.00% | - | - | ||
| Q2 2024 | -0.05 | -0.07 | 25.73% | -25.00% | - | - | ||
| Q1 2024 | -0.04 | -0.06 | 36.41% | 42.86% | - | - | ||
| Q4 2023 | -0.06 | -0.08 | 29.41% | - | - | - | ||
| Q3 2023 | -0.02 | -0.09 | 78.61% | 77.78% | - | - | ||
| Q2 2023 | -0.04 | -0.07 | 41.90% | 73.33% | - | - | ||
| Q1 2023 | -0.07 | -0.08 | 14.22% | 41.67% | - | - | ||
| Q4 2022 | -0.06 | -0.11 | 44.10% | 45.45% | - | - | ||
| Q3 2022 | -0.09 | -0.13 | 30.01% | 18.18% | - | - | ||
| Q2 2022 | -0.15 | -0.12 | -26.18% | -87.50% | - | - | ||
| Q1 2022 | -0.12 | -0.10 | -17.65% | -140.00% | - | - | ||
| Q4 2021 | -0.11 | -0.11 | -1.74% | -57.14% | - | - | ||
| Q3 2021 | -0.11 | -0.07 | -59.77% | -57.14% | 382.5K | -100.00% | - | |
| Q2 2021 | -0.08 | -0.08 | 4.93% | -14.29% | - | - | ||
| Q1 2021 | -0.05 | -0.05 | -8.93% | - | - | - | ||
| Q4 2020 | -0.07 | -0.05 | -52.51% | - | - | - | ||
| Q3 2020 | -0.07 | -0.07 | 6.41% | - | - | - | ||
| Q2 2020 | -0.07 | -0.07 | 1.96% | - | - | - | ||
| Q1 2020 | -0.05 | -0.08 | 38.73% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
35.11%
Max EPS beat (4)
132.68%
Min EPS beat (4)
-17.65%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, MDNA.CA has beaten EPS estimates in 3 out of 4 releases
In the last 4 quarters, MDNA.CA has beaten the EPS estimates by 35.1% on average.
Related analysis
MEDICENNA THERAPEUTICS CORP / MDNA.CA Earnings FAQ
Can you provide information on whether MEDICENNA THERAPEUTICS CORP beat earnings estimates in the last quarter?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) beat EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does MDNA stock beat earnings estimates?
In the last 4 quarters, MEDICENNA THERAPEUTICS CORP (MDNA.CA) has beaten EPS estimates in 3 out of 4 releases.